Company intelligence / Profile preview

Pinta Biotherapeutics, Inc.

California, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

PINTA 745 failed to meet its primary endpoint in a Phase 2 trial for protein energy wasting in end-stage renal disease patients. Development was halted in December 2015.

Therapeutic areas: Nephrology
Modalities: Peptibody
Industry: Biotech

Drug pipeline

5 assets

PINTA 745

Phase 2

Indications: Protein energy wasting, End-stage renal disease

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pinta Biotherapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pinta Biotherapeutics, Inc..

Explore the full profile